PE20091846A1 - DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS - Google Patents

DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS

Info

Publication number
PE20091846A1
PE20091846A1 PE2009000676A PE2009000676A PE20091846A1 PE 20091846 A1 PE20091846 A1 PE 20091846A1 PE 2009000676 A PE2009000676 A PE 2009000676A PE 2009000676 A PE2009000676 A PE 2009000676A PE 20091846 A1 PE20091846 A1 PE 20091846A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrrolo
difluoro
phenyl
pirrolo
Prior art date
Application number
PE2009000676A
Other languages
English (en)
Inventor
Prabha N Ibrahim
Wayne Spevak
Hanna Cho
Songyuan Shi
Original Assignee
Plexxikon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plexxikon Inc filed Critical Plexxikon Inc
Publication of PE20091846A1 publication Critical patent/PE20091846A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

REFERIDA A UN DERIVADO PIRROLO[2,3-d]-PIRIMIDINA DE FORMULA (I), DONDE LA LINEA ONDULADA REPRESENTA EL PUNTO DE UNION DE Ar A L1; LA LINEA ONDULADA DOBLE REPRESENTA EL PUNTO DE UNION DE Ar A L2; Ar ES UN GRUPO (a), (b), ENTRE OTROS; R12, R14, R15 Y R16 SON H, HALO, ALQUILO C1-C6, ENTRE OTROS; L1 ES -C(O)-, -O-, -S(O)2-, ENTRE OTROS; L2 ES -N(R8)-C(O)-, -N(R8)-S(O)-, -N(R8)-S(O)2, ENTRE OTROS; R8 ES H, ALQUILO C1-C6, ENTRE OTROS; R1 ES ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; R2 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, ENTRE OTROS; R3 ES H, ALQUILO C1-C6, ARILO C5-C7, ENTRE OTROS; R4 ES H, HALOGENO, AQLUILO C1-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: ACIDO PROPANO-1-SULFONICO {2,4-DIFLUORO-3-[HIDROXI-(7H-PIRROLO[2,3-d]PIRIMIDIN-5-IL)-METIL]-FENIL}-AMIDA, ACIDO PROPANO-1-SULFONICO [2,4-DIFLUORO-3-(7H-PIRROLO[2,3-d]PIRIMIDINA-5-CARBONIL)-FENIL]-AMIDA, N-2,4-DIFLUORO-3-[HIDROXI-(7H-PIRROLO[2,3-d]PIRIMIDIN-5-IL)-METIL]-FENIL-4-TRIFLUOROMETIL-BENCENSULFONAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE CINASAS, PARTICULARMENTE, Raf-QUINASAS Y SON UTILES EN EL TRATAMIENTO DE MELANOMA, CANCER COLORECTAL, ENFERMEDAD RENAL POLIQUISTICA, ENTRE OTROS
PE2009000676A 2008-05-19 2009-05-13 DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS PE20091846A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5444508P 2008-05-19 2008-05-19
US16381209P 2009-03-26 2009-03-26

Publications (1)

Publication Number Publication Date
PE20091846A1 true PE20091846A1 (es) 2009-12-16

Family

ID=41058596

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000676A PE20091846A1 (es) 2008-05-19 2009-05-13 DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS

Country Status (7)

Country Link
US (1) US8153641B2 (es)
AR (1) AR071838A1 (es)
CL (1) CL2009001212A1 (es)
PE (1) PE20091846A1 (es)
TW (1) TW200948815A (es)
UY (1) UY31829A (es)
WO (1) WO2009143024A2 (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
SG183036A1 (en) 2007-07-17 2012-08-30 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
CA2716947A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Imidazo [4,5-b] pyridine derivatives used as raf inhibitors
US8394795B2 (en) * 2008-02-29 2013-03-12 Array Biopharma Inc. Pyrazole [3, 4-B] pyridine Raf inhibitors
WO2009111278A2 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. Raf inhibitor compounds and methods of use thereof
WO2009111280A1 (en) * 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
CN101801015B (zh) * 2009-02-06 2014-03-12 中兴通讯股份有限公司 一种小区退服故障的处理方法及装置
BRPI1009090A2 (pt) 2009-03-26 2016-03-01 Takeda Pharmaceutical composto, pró-droga, medicamento, métodos, e, uso do composto
MX349923B (es) 2009-04-03 2017-08-21 Hoffmann La Roche Composiciones del ácido propano-1-sulfónico {3-[5-(4-cloro-fenil)- 1h-pirrolo [2,3-b]-piridina-3-carbonil]-2,4-difluoro-fenil]-amida y el uso de las mismas.
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
ES2633317T3 (es) 2009-11-06 2017-09-20 Plexxikon, Inc. Compuestos y métodos para la modulación de quinasas, e indicaciones para ello
BR112012011792A2 (pt) 2009-11-18 2015-10-13 Plexxikon Inc "compostos e métodos para modulação de quinases, e indicações para os mesmos"
RU2012131373A (ru) 2009-12-23 2014-01-27 Плексксикон, Инк. Соединения и способы модулирования киназы, а также показания для такого модулирования
WO2011082273A2 (en) * 2009-12-30 2011-07-07 Arqule, Inc. Substituted pyrrolo-aminopyrimidine compounds
TWI619713B (zh) 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
US9296811B2 (en) 2010-12-02 2016-03-29 University of Pittsburgh—of the Commonwealth System of Higher Education Methods for treating a tumor using an antibody that specifically binds HMW-MAA
MY162950A (en) 2011-02-07 2017-07-31 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
KR101298651B1 (ko) * 2011-03-16 2013-08-21 연세대학교 산학협력단 효능이 강화된 혈관신생 억제용 약제학적 조성물
MA35024B1 (fr) 2011-04-05 2014-04-03 Pfizer Ltd Dérivés de pyrrolo-[2,3-d]pyrimidine servant d'inhibiteurs des kinases apparentés à la tropomyosine
RU2631487C2 (ru) 2011-05-17 2017-09-22 Плексксикон Инк. Модуляция киназ и показания к её применению
JP6145451B2 (ja) 2011-07-08 2017-06-14 ノバルティス アーゲー 新規なピロロピリミジン誘導体
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
ES2889757T3 (es) 2012-09-06 2022-01-13 Plexxikon Inc Compuestos y procedimientos para la modulación de quinasas e indicaciones para estos
CA2885247A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Tropomyosin-related kinase inhibitors
EP2912036A1 (en) 2012-10-04 2015-09-02 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
JP2015531394A (ja) 2012-10-04 2015-11-02 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ ピロロ［２，３−ｄ］ピリミジントロポミオシン関連キナーゼ阻害剤
NZ711896A (en) 2012-12-21 2018-04-27 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
AU2014233437B2 (en) 2013-03-15 2018-07-26 Opna Immuno Oncology, SA Heterocyclic compounds and uses thereof
KR20160013028A (ko) 2013-05-30 2016-02-03 플렉시콘, 인코퍼레이티드 키나제 조정을 위한 화합물 및 그에 대한 적응증
CA2934010A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015134536A1 (en) 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2015159175A1 (en) 2014-04-15 2015-10-22 Pfizer Inc. Tropomyosin-related kinase inhibitors containing both a 1h-pyrazole and a pyrimidine moiety
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
CA2961356C (en) 2014-09-15 2023-03-07 Plexxikon Inc. Heterocyclic compounds and their uses in modulating bromodomain and for treating diseases or conditions relevant thereto
WO2016057367A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016164641A1 (en) 2015-04-08 2016-10-13 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
HUE050506T2 (hu) 2015-05-06 2020-12-28 Plexxikon Inc Kinázokat moduláló vegyület szilárd formái
ES2774178T3 (es) 2015-05-06 2020-07-17 Plexxikon Inc Síntesis de derivados de 1h-pirrolo[2,3-B] piridina que modulan cinasas
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
US20180194769A1 (en) 2015-07-06 2018-07-12 Rodin Therapeutics, Inc. Hetero-halo inhibitors of histone deacetylase
KR20180041135A (ko) 2015-07-16 2018-04-23 어레이 바이오파마 인크. Ret 키나아제 억제제로서 치환된 피라졸로[1,5-a]피리딘 화합물
US10829484B2 (en) 2015-07-28 2020-11-10 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
MX2018003432A (es) 2015-09-21 2018-06-08 Plexxikon Inc Compuestos heterociclicos y usos de los mismos.
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
MX2018006856A (es) 2015-12-07 2018-08-01 Plexxikon Inc Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos.
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2017133669A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh 5, 7-diazaindole and 5, 7-diazaindazole derivatives and their use in the treatment, amelioration or prevention of influenza
EP3430005B1 (en) 2016-03-16 2021-12-08 Plexxikon Inc. Compounds and methods for kinase modulation and indications therefore
TN2018000338A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Methods of treating pediatric cancers
BR112018070304A2 (pt) 2016-04-04 2019-01-29 Loxo Oncology Inc formulações líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
BR112018073504A2 (pt) 2016-05-18 2019-03-26 Array Biopharma, Inc. processo para preparar (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida e sais da mesma
MX2021009378A (es) * 2016-06-30 2022-06-29 Daewoong Pharmaceutical Co Ltd Derivados de pirazolopirimidina como inhibidor de cinasa.
CN107722013B (zh) * 2016-08-11 2021-01-12 中国科学院上海药物研究所 去氮嘌呤类化合物及其药物组合物、制备方法和用途
KR20190035925A (ko) 2016-08-24 2019-04-03 아르퀼 인코포레이티드 아미노-피롤로피리미디논 화합물 및 이의 사용 방법
TW201815766A (zh) 2016-09-22 2018-05-01 美商普雷辛肯公司 用於ｉｄｏ及ｔｄｏ調節之化合物及方法以及其適應症
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JP7193460B2 (ja) 2016-12-23 2022-12-20 プレキシコン インコーポレーテッド Ｃｄｋ８調節およびその適応症のための化合物および方法
AU2018207402B2 (en) 2017-01-11 2023-09-28 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
WO2018160824A1 (en) 2017-03-01 2018-09-07 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5 (prmt5)
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2018175311A1 (en) 2017-03-20 2018-09-27 Plexxikon Inc. Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1h- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain
WO2018226846A1 (en) 2017-06-07 2018-12-13 Plexxikon Inc. Compounds and methods for kinase modulation
CA3070505C (en) 2017-07-25 2023-09-26 Plexxikon Inc. Formulations of a compound modulating kinases
SG11202000970WA (en) 2017-08-07 2020-02-27 Rodin Therapeutics Inc Bicyclic inhibitors of histone deacetylase
TWI812649B (zh) 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
JP2020536917A (ja) 2017-10-13 2020-12-17 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼを調節するための化合物の固体形態
CN112165958A (zh) 2017-10-27 2021-01-01 普莱希科公司 调制激酶的化合物的制剂
JP7061195B2 (ja) 2018-01-18 2022-04-27 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［３，４－ｄ］ピリミジン化合物
CA3087354C (en) 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
JP2021518367A (ja) 2018-03-20 2021-08-02 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． Ｉｄｏおよびｔｄｏ調節のための化合物および方法、ならびにそれらのための兆候
CA3224949A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
ES2922314T3 (es) 2018-09-10 2022-09-13 Array Biopharma Inc Compuestos heterocíclicos condensados como inhibidores de cinasa RET
US20220081438A1 (en) 2018-12-19 2022-03-17 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
JP2022515197A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド がんを治療するためのｆｇｆｒ阻害剤としての７－（（３，５－ジメトキシフェニル）アミノ）キノキサリン誘導体
CN113710668A (zh) 2019-04-09 2021-11-26 普莱希科公司 用于ep300或cbp调节及其适应症的缩合吖嗪
CN110618271B (zh) * 2019-09-29 2023-06-13 中国医学科学院肿瘤医院 非小细胞肺癌的预后预测方法
IL294214A (en) 2019-12-27 2022-08-01 Schr?Dinger Inc Cyclic compounds and methods of using them
AU2021261383A1 (en) 2020-04-23 2022-11-17 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
US11628176B2 (en) 2020-08-21 2023-04-18 Opna Bio SA Combinational drug therapies
US20230365584A1 (en) 2020-09-10 2023-11-16 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
EP4284804A1 (en) 2021-01-26 2023-12-06 Schrödinger, Inc. Tricyclic compounds useful in the treatment of cancer, autoimmune and inflammatory disorders
TW202300150A (zh) 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
CN114409654A (zh) * 2021-12-30 2022-04-29 安徽普利药业有限公司 一种btk抑制剂的中间体合成方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3575977A (en) * 1968-08-14 1971-04-20 American Home Prod 7-alkyl-2,5-disubstituted-7h-pyrrolo-(2,3-d)pyrimidines-6-carbonitriles
PT2277551E (pt) 2002-09-06 2013-08-22 Cerulean Pharma Inc Polímeros à base de ciclodextrina para a administração de medicamentos ligados por ligação covalente
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
WO2005116035A1 (en) 2004-05-27 2005-12-08 Pfizer Products Inc. Pyrrolopyrimidine derivatives useful in cancer treatment
MX2007014377A (es) 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
TWI522337B (zh) 2005-06-22 2016-02-21 普雷辛肯公司 用於激酶調節的化合物及方法及其適應症

Also Published As

Publication number Publication date
TW200948815A (en) 2009-12-01
AR071838A1 (es) 2010-07-21
CL2009001212A1 (es) 2009-10-23
US8153641B2 (en) 2012-04-10
WO2009143024A2 (en) 2009-11-26
US20090286783A1 (en) 2009-11-19
UY31829A (es) 2010-01-05
WO2009143024A3 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
PE20091846A1 (es) DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS
PE20130602A1 (es) Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a
CY1118498T1 (el) Παραγωγα πυριδαζινονης
BRPI0514371A (pt) 2, 4 di (aminofenil) pirimidina como inibidores de plk
HRP20150941T1 (hr) Derivati aminodihidrotiazina kao inhibitori bace u lijeäśenju alzheimerove bolesti
EA201170237A1 (ru) Производные карбаматов алкилтиазолов, их получение и их применение в терапии
PE20091376A1 (es) Derivados de fenilamino como moduladores de beta-amiloide
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
NO20070122L (no) Quinazolinonderivater anvendelige som vanilloidantagonister
UY29886A1 (es) Derivados de pirazol novedosos, composiciones farmaccuticas que los contienen, procedimientos para la preparacinn de los mismos y aplicaciones
CY1111556T1 (el) Παραγωγα 2-βενζυλοπυριδαζινονης ως αναστολεις μετ-κινασης
EA200970669A1 (ru) Производные 2-амино-5,7-дигидро-6н-пирроло[3,4-d]пиримидина в качестве ингибиторов hsp-90, предназначенные для лечения рака
NO20076425L (no) Fremgangsmater for behandling av drug-resistent cancer
TW200502225A (en) Heterocyclic compounds useful as nurr-1 activators
AR060438A1 (es) 2-(piridin-2-il) - pirimidinas como fungicidas.
EA201171385A1 (ru) Производные циклопента[с]пирролилалкилкарбаматов 5-членных гетероциклов, способ их получения и применение их в терапии
RS53211B (en) PYRIDO [2,3-d] PYRIMIDINE DERIVATIVES, THEIR PRODUCTION, THEIR USE IN THERAPY
MXPA06010058A (es) Derivados de ester de rein y su uso terapeutico.
CY1112638T1 (el) Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον
HRP20080318T3 (en) Benzothiazole derivatives and use thereof in the treatment of diseases related to the adenosine a2a receptor
UY29894A1 (es) Derivados del ácido (2-((2s)-2-hidroxipropil)oxi)fenil)acético y del ácido (2-((2s)-2-hidroxipropil)oxi)fenil) propanoico sustituidos, composiciones farmacéuticas conteniéndolo, procesos de preparación y aplicaciones
EA200802248A1 (ru) Способы применения соединений 4-амино-5-хлортиено[2,3-d]-пиримидина в качестве инсектицидов
BRPI0808570B8 (pt) processo para a preparação de inibidores de glyt-1
ME01157B (me) DERlVATI 6-HETEROCIKLIČNOG-IMIDAZO[1,2-a]PIRIDIN-2 -KARBOKSAMIDA, NJIHOVA PRIPREMA I NJIHOVA PRIMJENA U LIJEČENJU
MX2009004979A (es) Sales de acidos dihidroxiantraquinona carboxilicos y su uso terapeutico.

Legal Events

Date Code Title Description
FD Application declared void or lapsed